- Trial phase
- Approved by FDA (Phase 3b TIW-dosing study ongoing)
- Time to market
- Already on the market (FDA approved March 27, 2024; commercial launch January 2025)
- Why 4/10
- Vafseo is already FDA-approved (March 2024) and commercially launched, with no pending PDUFA or pivotal new-indication readout, the defining binary has passed. The next hard catalyst is Phase 3b TIW-dosing topline data expected Q4 2026, which could support label expansion discussions but is not a make-or-break event. As an approved commercial-stage drug with no pending regulatory decision, the score is capped at 4.
Watch Q4 2026 for Phase 3b TIW-dosing topline data, positive results could unlock label expansion for three-times-weekly dosing, a commercial accelerator. The bigger overhang is the stalled non-dialysis expansion path (VALOR terminated Oct 2025), which caps the addressable market. Monitor quarterly Vafseo net revenue growth and whether Vafseo can offset the Auryxia generic erosion (Teva launched generic March 2026).
Price Chart
Executive Summary
Vafseo (vadadustat) is an oral HIF-PH inhibitor approved by the FDA in March 2024 for anemia due to chronic kidney disease in adults on dialysis. Akebia's commercial launch began January 2025, with Vafseo net revenue of $15.8M in Q1 2026 (up 32% YoY). A major positive catalyst hit on June 30, 2026, the VOICE trial interim analysis met stopping criteria, showing Vafseo reduced hospitalizations vs. standard ESAs. However, the stock has fallen ~51% over 12 months, weighed down by the October 2025 termination of the non-dialysis expansion (VALOR) trial and the March 2026 launch of generic competition for Auryxia (Akebia's other product). Vafseo is the central value driver at a company with a ~$248M market cap, high short interest (~14% of float), and a pipeline of early-stage rare kidney disease assets.
How It Works
Vafseo is an oral pill taken once daily (with potential for three-times-weekly dosing). It works by tricking the body into thinking it's at high altitude, which stimulates natural production of erythropoietin (EPO), the hormone that tells bone marrow to make more red blood cells. This helps correct anemia in kidney disease patients who can't produce enough EPO naturally. It's a HIF-PH inhibitor, a different approach than injectable ESA drugs (like Epogen) that deliver synthetic EPO from outside the body.
Trial Status
Vafseo was approved based on the Phase 3 INNO2VATE program. A Phase 3b TIW (three-times-weekly dosing) study (NCT06901505) is active, not recruiting, with ~353 patients enrolled and topline data expected Q4 2026. The Phase 4 VOICE outcomes trial (~2,200 patients) hit its interim stopping criteria on June 30, 2026, showing Vafseo was non-inferior and superior to standard ESAs on a composite of mortality and hospitalization. The planned Phase 3 VALOR trial for non-dialysis patients was terminated in October 2025 after the FDA rejected the trial design as too costly and time-consuming.
The Two-Sided Case
Upcoming Catalysts
- Phase 3b TIW-dosing topline data (Q4 2026), could enable label expansion for three-times-weekly dosing, a key commercial differentiator in dialysis centers
- Full VOICE trial completion and formal publication (early 2027), the interim already hit, but full data could reinforce the hospitalization benefit thesis
- VOICE data submission for presentation at an upcoming scientific meeting
- Praliciguat Phase 2 initial data for focal segmental glomerulosclerosis (FSGS), rare kidney disease pipeline
- Quarterly earnings reports tracking Vafseo revenue growth vs. Auryxia erosion
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Akebia Therapeutics, Inc. 8-K AKBA ·Originating report